HealthTree Logo
search more_vert
App Logo
close
person Sign In / Create Account

Clinical Trial

Recruiting

Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies

          This clinical trial studies reduced-intensity conditioning before donor stem cell transplant in treating patients with high-risk hematologic malignancies. Giving low-doses of chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor lymphocyte infusion) after the transplant may help increase this effect.
        

Est. Enrollment: 72 participants

info
The number of participants in a clinical study. The "estimated" enrollment is the target number of participants the researchers need for the study.

Study Start Date: Dec 24, 2012

info
These are the dates the researchers think the study will start and end.

Study Completion Date: Sep 01, 2022

info
The "estimated" study completion date is the date the researchers think the last participant in a clinical study was examined or received an intervention/treatment. This is also the expected date that the study will be completed

Age: 18+ years

Gender: All

Who can join expand_less
  • Any patient with a high-risk hematologic or oncologic diagnosis in which allogeneic HSCT is thought to be beneficial, and in whom front-line therapy has already been applied. High risk is defined as:
  • Acute myeloid leukemia with high risk features as defined by:
  • Age greater than or equal to 60
  • Secondary AML (prior therapy or hematologic malignancy)
  • Normal cytogenetics but FLT3/ITD positive
  • Any relapse or primary refractory disease
  • Greater than 3 cytogenetic abnormalities or any one of the following cytogenetic abnormalities: -5/del(5q), -7/del(7q), Abn(9q),(11q),(3q),(21q),(17p),t(6;9), t(6;11), t(11;19), +8,del(12p),inv(3),t(10;11),-17, 11q 23
  • Any single autosomal monosomy
  • Acute lymphoid leukemia in 1st or 2nd morphological remission. ALL with any morphological evidence of disease will not be eligible.
  • Myelodysplasia (MDS) other than refractory anemia (RA), refractory anemia with rare sideroblasts (RARS), or isolated 5q- syndrome subtypes.
  • Hodgkin's or Non-Hodgkin's lymphoma in 2nd or greater remission or with persistent disease.
  • Myeloma with evidence of persistent disease after front-line therapy.
  • Chronic myeloid leukemia (CML) resistant to signal transducer inhibitor (STI) therapy
  • Myelofibrosis and CMML
  • Essential Thrombocytopenia or Polycythemia Vera with current or past evidence of evolution to acute leukemia
  • Any hematological malignancy not cited above which is thought to be high-risk with increased chance of post HSCT relapse. Patients in this category require specific approval of the PI and the TJU BMT attending physician group for entrance.
  • Any hematological malignancy or dyscrasia not cited above which is thought to be high-risk with increased chance of post HSCT relapse.
  • Any patient who has an aggressive disease that would normally be treated on a myeloablative study, but is prevented from doing so by factors in their past medical history. Examples are patients with previous treatment with radiation therapy precluding TBI, or a past history of myeloablative therapy, precluding a 2nd myeloablative regimen.
  • Patients with aplastic anemia may be treated on this protocol, with outcomes reported descriptively.
  • Patients must have a related donor who is at least a 4 antigen match at the Human Leukocyte Antigen (HLA)-A; B; C; DR loci. Patients with only a 1 out of 8 mismatch in the GVH direction will be classified in the matched related category
  • Patients must adequate organ function:
  • Left ventricular end diastolic function (LVEF) of >50%
  • Diffusion Lung Capacity of Oxygen (DLCO) >50% of predicted corrected for hemoglobin
  • Adequate liver function as defined by a serum bilirubin <1.8, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2.5X upper limit of normal
  • Creatinine Clearance of ≥ 60 mL/min 4) Patients must have adequate KPS and HCT-CI scores:
  • Patients < age 60 years must have a KPS of ≥80% and an HCT-CI score of 5 or less
  • Patients aged 60 to 65 years must have a KPS of ≥80% and an HCT-CI score of 4 or less
  • Patients aged 66 to 69 years must have a KPS of 90% and an HCT-CI score of 3 or less
  • Patients aged 70 years or more must have a KPS of 90% and an HCT-CI score of 2 or less (Patients with greater than the allowable HCT-CI points for age can be enrolled for trial with approval of the PI and at least 1 Co-I not on the primary care team of the patient). This is an adjustment to account for healthy patients who meet the spirit of the protocol but have histories that result in higher than guideline HCT-CI points. An examples is a patient with a solid tumor malignancy in their remote history (adds 3 points to HCT-CI total) where the treatment for the malignancy occurred years to decades before and there has been complete recovery of toxicities 5) Patients must be willing to use contraception if they have childbearing potential 6) Patient or patient's guardian is able to give informed consent
Who cannot join expand_less
  • HIV positive
  • Active involvement of the central nervous system with malignancy
  • Pregnancy
  • Patients with life expectancy of < 6 months for reasons other than their underlying hematologic/oncologic disorder
  • Patients who have received alemtuzumab or ATG within 8 weeks of the transplant admission.
  • Patients with evidence of another malignancy, exclusive of a skin cancer that requires only local treatment, should not be enrolled on this protocol
Study Description expand_more
Study Details expand_more

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Abbvie
Genentech
GSK
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube